This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up
by Zacks Equity Research
If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
Corvus Starts Immunotherapy Study on Coronavirus, Stock Rises
by Zacks Equity Research
Shares of Corvus (CRVS) rise as it commences a phase I study to investigate a novel immunotherapy approach for patients with COVID-19.
Novartis Gets EC Approval for Enerzair Breezhaler for Asthma
by Zacks Equity Research
Novartis (NVS) gets EC approval for Enerzair Breezhaler as a maintenance treatment for asthma.
Immunomedics' Shares Rise on Positive Breast Cancer Drug Data
by Zacks Equity Research
Shares of Immunomedics (IMMU) rise after it announces positive phase III data for its breast-cancer drug, Trodelvy.
Here's Why Lilly (LLY) Stock is Up Despite Coronavirus Crisis
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.
Immunomedics' Shares Surge YTD on Cancer Drug Approval
by Zacks Equity Research
Immunomedics' (IMMU) share price rises on the receipt of its first FDA approval for Trodelvy to treat metastatic triple-negative breast cancer patients.
Seattle Genetics' Adcetris Progresses Well Amid Competition
by Zacks Equity Research
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. Further, label expansions of the drug should continue to boost the top line.
4 Reasons to Own AbbVie Stock as Coronavirus Woes Linger
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
Gilead's Coronavirus Drug Gets Conditional Approval in Europe
by Zacks Equity Research
Gilead (GILD) gets conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection by the European Commission.
Pharma Stock Roundup: PFE's Coronavirus Vaccine Study, Approvals in Focus
by Kinjel Shah
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug
by Zacks Equity Research
Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.
Gilead's Coronavirus Drug Being Stocked by the US Government
by Zacks Equity Research
Gilead's (GILD) coronavirus drug, remdesivir, is being stocked by the Trump administration through September.
Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial
by Zacks Equity Research
Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.
RedHill (RDHL) to Study Opaganib for Severe Coronavirus in UK
by Zacks Equity Research
RedHill's (RDHL) CTA gets approval in the United Kingdom to start a phase II/III study on opaganib for patients hospitalized with severe COVID-19 infection and pneumonia.
Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a fixed-dose combination of Perjeta and Herceptin, Phesgo, plus chemotherapy as a treatment for HER2-positive breast cancer.
Sarepta Completes Rolling NDA Submission for New DMD Therapy
by Zacks Equity Research
Sarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.
Theravance Doses First Patient in Phase II Coronavirus Study
by Zacks Equity Research
Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation
by Zacks Equity Research
Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.
AbbVie's Eye Disorder Candidate Gets Complete Response Letter
by Zacks Equity Research
AbbVie (ABBV) unit Allergan's abicipar pegol demonstrates unfavorable benefit-risk ratio in patients with nAMD, an eye disorder. The FDA issues a complete response letter.
Global Blood to Seek Approval of Oxbryta in Europe for SCD
by Zacks Equity Research
Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.
FibroGen Begins Phase II Study for Acute Coronavirus in US
by Zacks Equity Research
FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.
Karyopharm's Xpovio Gets FDA Accelerated Approval for DLBCL
by Zacks Equity Research
Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in relapsed or refractory diffuse large B-cell lymphoma.
Sarepta Inks Agreement With Codiak to Develop Gene Therapies
by Zacks Equity Research
Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.
Gilead to Start Studies for an Inhaled Version of Remdesivir
by Zacks Equity Research
Gilead (GILD) announces plans to start studies for an inhaled version of the experimental candidate, remdesivir, in August.
Epizyme Gets FDA Nod for Tazverik sNDA in Follicular Lymphoma
by Zacks Equity Research
The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.